I.V. Keppra "approvable," quick response
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
UCB has responded to a recent "approvable" letter for an intravenous formulation of its antiepileptic Keppra (levetiracetam), the firm reports Feb. 3. FDA had requested "revised product labeling as well as some additional information regarding manufacturing to finalize its review," UCB says. The company hopes I.V. Keppra will be of use in "emergency seizure situations where oral medication is not an option." Keppra would be the first of the newer antiepileptics to be available intravenously, according to UCB. Also on Feb. 3, the formulation received a positive opinion from the European Medicines Agency...
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.